SCHEMBL5146497

SCHEMBL5146497

COc1ccc2c(c1)C(N(Cc1ccccc1)C[C@H](O)COc1ccccc1)CCCC2

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.49
WDR77 Q9BQA1 2/20 0.49
ALDH1A1 P00352 2/20 0.47
TSHR P16473 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.42
DRD4 P21917 1/20 0.41
CASR P41180 1/20 0.41
GAA P10253 1/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143652 0.82 ALDH1A1 (0.48) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5143959 0.82 ALDH1A1 (0.48) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5144161 0.78 DRD2 (0.45) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5143855 0.76 PRMT5 (0.47) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL24827556 0.74 TAS2R14 (0.46) MEN1KMT2ATAS2R14SIGMAR1
SCHEMBL5143739 0.74 PRMT5 (0.46) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5142021 0.74 MAPT (0.45) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5143628 0.73 PRMT5 (0.45) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5146452 0.73 PRMT5 (0.48) PRMT5WDR77ALDH1A1TSHRMEN1
SCHEMBL5144084 0.73 PRMT5 (0.46) PRMT5WDR77ALDH1A1TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217706-B2 Propanolamine derivatives ASTELLAS PHARMA INC. (JP) 2007-05-15 US disclosed
EP-1382333-A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-21 EP disclosed
US-6495546-B1 SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
US-20020120148-A1 Propanolamine derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-08-29 US disclosed
EP-1070046-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed
WO-1999051564-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120148-A1 Propanolamine derivatives AMY2A, PNMT, PNLIP PRMT5 849/4885WDR77 2347/4885ALDH1A1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.